Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 370 citing articles:

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
Yasmin L. Hurd, Sharron Spriggs, Julia Alishayev, et al.
American Journal of Psychiatry (2019) Vol. 176, Iss. 11, pp. 911-922
Closed Access | Times Cited: 278
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney, Dominic Oliver, Alastair Green, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 11, pp. 1799-1806
Open Access | Times Cited: 221
Cannabidiol: pharmacology and therapeutic targets
Stevie C. Britch, Shanna Babalonis, Sharon Walsh
Psychopharmacology (2020) Vol. 238, Iss. 1, pp. 9-28
Open Access | Times Cited: 220
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Jakub Mlost, Marta Bryk, Katarzyna Starowicz
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8870-8870
Open Access | Times Cited: 215
Medicinal use of cannabis based products and cannabinoids
Tom P. Freeman, Chandni Hindocha, Sebastian F Green, et al.
BMJ (2019), pp. l1141-l1141
Open Access | Times Cited: 202
30 years of second-generation antiseizure medications: impact and future perspectives
Emilio Perucca, Martin J. Brodie, Patrick Kwan, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 6, pp. 544-556
Closed Access | Times Cited: 179
A Review of Hemp as Food and Nutritional Supplement
Pellegrino Cerino, Carlo Buonerba, Giuseppe Cannazza, et al.
Cannabis and Cannabinoid Research (2020) Vol. 6, Iss. 1, pp. 19-27
Open Access | Times Cited: 176
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison, Julie C. Crockett, Graham Blakey, et al.
Clinical Pharmacology in Drug Development (2019) Vol. 8, Iss. 8, pp. 1009-1031
Open Access | Times Cited: 175
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Towards Better Delivery of Cannabidiol (CBD)
Sophie Millar, Ryan Maguire, Andrew Yates, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 9, pp. 219-219
Open Access | Times Cited: 172
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Gavin M. Traber, Ai‐Ming Yu
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 384, Iss. 1, pp. 133-154
Open Access | Times Cited: 167
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects
Nadia Solowij, Samantha J. Broyd, Lisa‐Marie Greenwood, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 269, Iss. 1, pp. 17-35
Open Access | Times Cited: 161
Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials
Christian Larsen, Jorida Shahinas
Journal of Clinical Medicine Research (2020) Vol. 12, Iss. 3, pp. 129-141
Open Access | Times Cited: 148
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147
Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process
Arun Bhaskar, Alan Bell, Michael Boivin, et al.
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 115
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
Long C. Nguyen, Dongbo Yang, Vlad Nicolaescu, et al.
Science Advances (2022) Vol. 8, Iss. 8
Open Access | Times Cited: 113
Molecular and Cellular Mechanisms of Action of Cannabidiol
Nadia Martínez Naya, Jazmin Kelly, Giuliana Corna, et al.
Molecules (2023) Vol. 28, Iss. 16, pp. 5980-5980
Open Access | Times Cited: 55
An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects
Nadia Martínez Naya, Jazmin Kelly, Giuliana Corna, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 473-473
Open Access | Times Cited: 22
Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies
Anastasia Suraev, Nathaniel S. Marshall, Ryan G. Vandrey, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101339-101339
Closed Access | Times Cited: 134
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications
Emilio Perucca, Meir Bialer
CNS Drugs (2020) Vol. 34, Iss. 8, pp. 795-800
Closed Access | Times Cited: 124
Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats
Kelly A. Deabold, Wayne S. Schwark, Lisa Wolf, et al.
Animals (2019) Vol. 9, Iss. 10, pp. 832-832
Open Access | Times Cited: 121
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Yann Chye, Erynn Christensen, Nadia Solowij, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 119
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
Yuli Qian, Bill J. Gurley, John S. Markowitz
Journal of Clinical Psychopharmacology (2019) Vol. 39, Iss. 5, pp. 462-471
Closed Access | Times Cited: 110
The Essential Medicinal Chemistry of Cannabidiol (CBD)
Kathryn M. Nelson, Jonathan Bisson, Gurpreet Singh, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12137-12155
Open Access | Times Cited: 109
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms
Ewa Galaj, Guo‐Hua Bi, Hongju Yang, et al.
Neuropharmacology (2019) Vol. 167, pp. 107740-107740
Open Access | Times Cited: 106
Page 1 - Next Page

Scroll to top